Plasmapheresis of the Patient as a Method for Achieving Effective Levels of Plasma Coagulation Factors Using Fresh Frozen Plasma

Transfusion ◽  
1966 ◽  
Vol 6 (4) ◽  
pp. 293-301
Author(s):  
Herbert A. Perkins
Keyword(s):  
Coagulation Factors ◽  
Fresh Frozen Plasma ◽  
Plasma Coagulation ◽  
Fresh Frozen ◽  
Frozen Plasma

EPTACOG ALFA. APPLICATION EXPERIENCE

2017 ◽  
Author(s):  
И. Нехаев ◽  
А. Приходченко ◽  
С. Ломидзе ◽  
А. Сытов
Keyword(s):  
Intensive Care Unit ◽  
Malignant Tumors ◽  
Coagulation Factors ◽  
Fresh Frozen Plasma ◽  
Massive Bleeding ◽  
Threshold Concentration ◽  
Damage Area ◽  
Fresh Frozen ◽  
Hemostatic Therapy ◽  
Frozen Plasma

Введение. Несмотря на переливания свежезамороженной плазмы и тромбоцитов, часто не удается достигнуть нужной «пороговой» концентрации факторов свертывания при массивных кровотечениях. При введении рекомбинантного активированного VII фактора (rFVIIa, эптаког альфа) этот процесс может быть ускорен, происходит «тромбиновый взрыв», который обеспечивает образование стабильной фибриновой пробки. Цель исследования: оценка эффективности и безопасности применения rVIIа в онкохирургии при коагулопатических кровотечениях. Материалы и методы. Обследовано 38 пациентов, оперированных по поводу злокачественных новообразований различной локализации, находившихся на лечении в отделении реанимации и интенсивной терапии № 1 в течение 2014 года. Результаты. Клиническая эффективность rFVIIа составила 94,7% при неэффективности стандартной гемостатической терапии и исчерпанных возможностях хирургического гемостаза при коагулопатических кровотечениях у онкохирургических больных. Заключение. rFVIIа обладает селективным действием (действует в зоне повреждения), что подтверждают данные коагулограммы и тромбоэлаcтометрии. rFVIIа не утяжеляет состояния больных. Introduction. Despite the transfusion of fresh frozen plasma and platelets it is often not possible to achieve the desired «threshold» concentration of coagulation factors in case of acute massive bleeding. Administration of recombinant activated VII factor (rFVIIa, eptacog alfa) can accelerates this process; «thrombin burst» occurs that provides the formation of a stable fi brin plug. Aim: to assess the effectiveness and safety of rVIIa usage in oncosurgery at coagulopathic bleedings. Materials and methods. In intensive care unit during 2014 we examined 38 patients with malignant tumors of various locations after surgery. Results. Clinical efficacy of rFVIIa was 94,7% with ineffectiveness of standard hemostatic therapy and exhausted possibilities of surgical hemostasis with coagulopathic bleedings in oncosurgical patients. Conclusion. rFVIIa has a targeted action (acts in damage area); coagulogram and thromboelometry data prove its action. rFVII does not make patients worse.

Comparison of the coagulation potential of lyophilized blood plasma virus-inactivated by two different methods.

2021 ◽  
Author(s):  
И.А. Кривов ◽  
А.А. Рагимов ◽  
Э.Л. Салимов
Keyword(s):  
Comparative Evaluation ◽  
Room Temperature ◽  
Coagulation Factors ◽  
Fresh Frozen Plasma ◽  
Activated Partial Thromboplastin Time ◽  
Plasma Virus ◽  
Coagulation Parameters ◽  
Normal Limits ◽  
Fresh Frozen ◽  
Frozen Plasma

Введение. Свежезамороженная плазма (СЗП) — один из самых распространённых компонентов крови, применяемых сегодня в клиниках при оказании медицинской помощи при кровотечениях и тяжёлых коагулопатиях. В отличие от вирусинактивированной замороженной плазмы, сублимированная (лиофилизированная) плазма может храниться при комнатной температуре, и восстановление перед переливанием обычно требует меньших временных затрат. Цель исследования: оценить коагуляционный потенциал лиофилизированной плазмы, полученной из вирусинактивированной плазмы, инактивированной 2 способами: с использованием метиленового синего + видимый свет и рибофлавина + ультрафиолетовое облучение спектра B. Материалы и методы. Проведен анализ 100 образцов иофилизированной плазмы, вирусинактивированной двумя методами. Изучали влияние лиофилизации на уровень факторов свертывания и показатели свертываемости в вирусинактивированной плазме. Для сравнительной оценки в качестве контроля были проанализированы 150 образцов СЗП. Результаты. При использовании обоих технологий инактивации в лиофилизированной вирусинактивированной плазме установлено снижение содержания факторов V и VIII как по отношению к СПЗ, так и по отношению к физиологической норме. Лиофилизация вирусинактивированной плазмы различными методами привела к некоторому увеличению показателей свёртывания крови — протромбинового времени и активированного частичного тромбопластинового времени. Остальные показатели оставались в нормальных пределах. Существенных различий в показателях между образцами плазмы, инактивированной различными методами, выявлено не было. Заключение. По клиническим свойствам вирусинактивированная лиофилизированная плазма может служить альтернативой СЗП, однако для уточнения всесторонних аспектов её применения необходимы дополнительные исследования. Introduction. Fresh frozen plasma (FFP) is one of the most common blood components used today in clinics for medical care of bleeding and severe coagulopathies. Unlike virus-inactivated frozen plasma, sublimated (lyophilized) plasma can be stored at room temperature, and recovery before transfusion usually requires less time. Objectives: to assess the coagulation potential of lyophilized plasma obtained from virus- inactivated plasma inactivated by 2 methods: using methylene blue + visible light and riboflavin + ultraviolet radiation of spectrum B. Materials/Methods. Analysis of 100 samples of lyophilized plasma, virus-inactivated by 2 methods, was carried out. The effect of lyophilization on the level of coagulation factors and coagulation parameters in virus-inactivated plasma was studied. For comparative evaluation, 150 samples of FFP were analyzed as a control. Results. Using both technologies for inactivation of lyophilized virus- inactivated plasma, a decrease in the content of V and VIII factors was found both in relation to the FFP and in relation to the physiological norm. Lyophilization of virus-inactivated plasma by various methods led to a slight increasing in blood coagulation parameters — prothrombin time and activated partial thromboplastin time. The rest of the parameters remained within normal limits. There were no significant differences in parameters between plasma samples inactivated by different methods. Conclusions. According clinical properties, virus- inactivated lyophilized plasma can serve as an alternative to FFP, but more studies are needed to clarify the comprehensive aspects of its use.

scholarly journals ACTIVITIES OF COAGULATION FACTORS IN FRESH FROZEN PLASMA AFTER LONG-TERM STORAGE

2016 ◽  
Vol 62 (4) ◽  
pp. 545-551
Author(s):  
Akihiro Fuchizaki ◽  
Jumpei Mori ◽  
Akira Iwama ◽  
Masayuki Shiba ◽  
Yu Naito ◽  
...  
Keyword(s):  
Coagulation Factors ◽  
Fresh Frozen Plasma ◽  
Long Term Storage ◽  
Fresh Frozen ◽  
Term Storage ◽  
Frozen Plasma

Influence of Methylene Blue Photoinactivation Treatment on Coagulation Factors from Fresh Frozen Plasma, Cryoprecipitates and Cryosupernatants

Vox Sanguinis ◽  
2000 ◽  
Vol 79 (3) ◽  
pp. 156-160 ◽  
Author(s):  
J.A. Aznar ◽  
S. Bonanad ◽  
J.M. Montoro ◽  
C. Hurtado ◽  
A.R. Cid ◽  
...  
Keyword(s):  
Methylene Blue ◽  
Coagulation Factors ◽  
Fresh Frozen Plasma ◽  
Fresh Frozen ◽  
Frozen Plasma

Comparison of the coagulation potential of lyophilized blood plasma virus-inactivated by various methods

2020 ◽  
pp. 49-60
Author(s):  
Ivan Krivov ◽  
Aligejdar Ragimov ◽  
Emin Salimov ◽  
Karim Magadeev ◽  
Yana Mishutkina
Keyword(s):  
Methylene Blue ◽  
Visible Light ◽  
Ultraviolet Irradiation ◽  
Coagulation Factors ◽  
Fresh Frozen Plasma ◽  
Research Data ◽  
Blood Coagulation Factors ◽  
Plasma Virus ◽  
Fresh Frozen ◽  
Frozen Plasma

The article presents research data on the conservation of coagulation potential of lyophilized plasma inactivated by three different technologies — amotosalen and ultraviolet irradiation of spectrum A, riboflavin + ultraviolet of spectrum B, methylene blue + visible light. The study analyzed the concentration of blood-coagulation factors that affect the extrinsic, intrinsic and general coagulation pathways by comparing samples of virus-inactivated lyophilized plasma with various inactivation methods. As a result of the study, no significant differences in the indices between samples of plasma inactivated by various methods were detected. Therefore, virus-inactivated lyophilized plasma can serve as a full alternative to fresh frozen plasma.

scholarly journals Stability of Thawed Apheresis Fresh-Frozen Plasma Stored for up to 120 Hours at 1°C to 6°C

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
William P. Sheffield ◽  
Varsha Bhakta ◽  
Qi-Long Yi ◽  
Craig Jenkins
Keyword(s):  
Prothrombin Time ◽  
Closed System ◽  
Whole Blood ◽  
Coagulation Factors ◽  
Fresh Frozen Plasma ◽  
Refrigerated Storage ◽  
Fresh Frozen ◽  
Frozen Plasma ◽  
Over Time ◽  
Made In

Regulations concerning the storage of transfusable plasma differ internationally. In Canada, plasma obtained from whole blood donations and frozen within 24 hours of phlebotomy (frozen plasma, FP) may be thawed and transfused within 120 hours of refrigerated storage. However, plasma frozen within 8 hours of phlebotomy following apheresis donation (FFPA) must be transfused within 24 hours of thawing and refrigeration. Our objectives were to measure coagulation factors (F) V, VII, and VIII, fibrinogen activities, and the prothrombin time (PT) in thawed refrigerated FFPA at 0, 24, and 120 hours of storage and to compare these values to those in thawed refrigerated FP. Fibrinogen activity remained unchanged over time, while mean factor levels in 28 FFPA units declined by 17% (FV), 19.7% (FVII), and 54.6% (FVIII) over 120 hours, while PT values rose to 7.6%. Factor activities were significantly higher in FFPA than FP after 120 hours of refrigerated storage. Residual FVIII activities in thawed FFPA met predefined noninferiority criteria compared to thawed FP after 120 hours. These results support a change in Canadian regulations to permit transfusion of thawed FFPA made in a closed system and refrigerated for up to 120 hours, one that could reduce wastage of transfusable plasma.

Labile Coagulation Factors in Thawed Fresh Frozen Plasma Prepared by Two Methods

Vox Sanguinis ◽  
1984 ◽  
Vol 46 (1) ◽  
pp. 44-46 ◽  
Author(s):  
Ram. M. Kakaiya ◽  
Edward E. Morse ◽  
Sophia Panek
Keyword(s):  
Coagulation Factors ◽  
Fresh Frozen Plasma ◽  
Fresh Frozen ◽  
Frozen Plasma

scholarly journals Coagulation profile of human COVID-19 convalescent plasma

2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Allan M. Klompas ◽  
Noud van Helmond ◽  
Justin E. Juskewitch ◽  
Rajiv K. Pruthi ◽  
Matthew A. Sexton ◽  
...  
Keyword(s):  
Coagulation Factor ◽  
Protein S ◽  
Coagulation Factors ◽  
Fresh Frozen Plasma ◽  
Thrombin Time ◽  
Fresh Frozen ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Plasmin Inhibitor ◽  
Frozen Plasma

AbstractConvalescent plasma is used to treat COVID-19. There are theoretical concerns about the impact of pro-coagulant factors in convalescent plasma on the coagulation cascade particularly among patients with severe COVID-19. The aim of this study was to evaluate the coagulation profile of COVID-19 convalescent plasma. Clotting times and coagulation factor assays were compared between fresh frozen plasma, COVID-19 convalescent plasma, and pathogen-reduced COVID-19 convalescent plasma. Measurements included prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, D-dimer, von Willebrand factor activity, von Willebrand factor antigen, coagulation factors II, V, VII–XII, protein S activity, protein C antigen, and alpha-2 plasmin inhibitor. Clotting times and coagulation factor assays were not different between COVID-19 convalescent plasma and fresh frozen plasma, except for protein C antigen. When compared to fresh frozen plasma and regular convalescent plasma, pathogen reduction treatment increased activated partial thromboplastin time and thrombin time, while reducing fibrinogen, coagulation factor II, V, VIII, IX, X, XI, XII, protein S activity, and alpha-2 plasmin inhibitor. The coagulation profiles of human COVID-19 convalescent plasma and standard fresh frozen plasma are not different. Pathogen reduced COVID-19 convalescent plasma is associated with reduction of coagulation factors and a slight prolongation of coagulation times, as anticipated. A key limitation of the study is that the COVID-19 disease course of the convalesced donors was not characterized.

Sign in / Sign up

Export Citation Format

Share Document